Spero Therapeutics, INC Form 4 insider transactions

Debra Zack, Chief Medical Officer of Spero Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.

Spero Therapeutics Director Milind Deshpande acquired 10,000 restricted stock units and was granted an option to purchase 20,000 shares.

Kathleen Tregoning, a Director at Spero Therapeutics, Inc., reported the acquisition of 10,000 restricted stock units and 20,000 stock options.

Spero Therapeutics Director Cynthia Smith acquired 10,000 shares of common stock and was granted an option to purchase 20,000 shares.

Spero Therapeutics Director Patrick Vink acquired 10,000 restricted stock units and was granted an option to purchase 20,000 shares.

Spero Therapeutics Director Frank E. Thomas acquired 10,000 restricted stock units and was granted options for 20,000 shares.

Spero Therapeutics Director Scott Thomas Jackson reported the acquisition of 10,000 restricted stock units and 20,000 stock options.

John C. Pottage Jr., a Director at Spero Therapeutics, Inc., acquired 10,000 restricted stock units and was granted an option to purchase 20,000 shares.

Esther Rajavelu, CEO of Spero Therapeutics, executed a non-discretionary sale of 25,240 shares to cover tax liabilities from RSU vesting.

Esther Rajavelu, an officer at Spero Therapeutics, sold 87,917 shares of common stock to cover tax withholding obligations related to RSU vesting.

Spero Therapeutics' Chief Operating Officer, Timothy Keutzer, sold 18,652 shares of common stock to cover tax withholding obligations related to RSU vesting.

Spero Therapeutics' Chief Operating Officer, Timothy Keutzer, reported the acquisition of restricted stock units and stock options, alongside 'sell to cover' transactions for tax obligations.

Spero Therapeutics' multi-titled officer, Esther Rajavelu, was granted 249,000 restricted stock units and 498,000 stock options, alongside a tax-related sale of 18,442 shares.

Spero Therapeutics' multi-titled officer, Esther Rajavelu, sold 40,270 shares of common stock at $2.37 per share to cover tax withholding obligations related to RSU vesting.

Spero Therapeutics Director Ankit Mahadevia sold 6,572 shares of common stock at $1.97 per share to cover tax withholding obligations related to RSU vesting.

Spero Therapeutics' Chief Operating Officer, Timothy Keutzer, sold 1,695 shares of common stock to cover tax withholding obligations related to RSU vesting.

Spero Therapeutics, Inc. Director Ankit Mahadevia was granted 20,000 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Spero Therapeutics, Inc. Director Milind Deshpande was granted 20,000 restricted stock units (RSUs) on June 12, 2025, increasing his total beneficial ownership to 91,454 shares.

Spero Therapeutics, Inc. Director Scott Thomas Jackson was granted 20,000 Restricted Stock Units (RSUs) on June 12, 2025, as part of his compensation.

Spero Therapeutics, Inc. Director Patrick V.J.J. Vink was granted 20,000 restricted stock units (RSUs) on June 12, 2025, increasing his total beneficial ownership to 75,000 shares.

Spero Therapeutics, Inc. Director John C. Pottage Jr. was granted 20,000 restricted stock units (RSUs) as part of his compensation, vesting in June 2026.

Spero Therapeutics Director Cynthia Smith was granted 20,000 restricted stock units (RSUs) on June 12, 2025, increasing her beneficial ownership to 75,000 shares.

Spero Therapeutics, Inc. Director Frank E. Thomas was granted 20,000 Restricted Stock Units (RSUs) on June 12, 2025, which will vest in one year.

Spero Therapeutics, Inc. Director Kathleen Tregoning was granted 20,000 restricted stock units (RSUs) on June 12, 2025, which are set to vest on June 12, 2026.

Esther Rajavelu, a key executive at Spero Therapeutics, has reported acquiring 185,000 shares of common stock through restricted stock units.

Timothy Keutzer, Chief Operating Officer of Spero Therapeutics, reports the acquisition and disposal of common stock related to restricted stock units.

Esther Rajavelu, CFO & CBO of Spero Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Sath Shukla, CEO of Spero Therapeutics, reports the acquisition and disposal of common stock related to restricted stock units (RSUs) vesting.

Director Ankit Mahadevia sold shares of Spero Therapeutics common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Esther Rajavelu, CFO & CBO of Spero Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting RSUs.